Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Future Treatment Strategy for Esophageal Cancer Based on Prediction of Systemic Recurrence: Significance of Pathologic Nodal Status After Neoadjuvant Chemotherapy

Future Treatment Strategy for Esophageal Cancer Based on Prediction of Systemic Recurrence:... Ann Surg Oncol (2018) 25:2127–2128 https://doi.org/10.1245/s10434-018-6544-0 ED ITORIA L – G A STROI N TESTIN A L O NCOL OG Y Future Treatment Strategy for Esophageal Cancer Based on Prediction of Systemic Recurrence: Significance of Pathologic Nodal Status After Neoadjuvant Chemotherapy Takushi Yasuda, MD Department of Surgery, Faculty of Medicine, Kindai University, Osaka-Sayama, Osaka , Japan The main goals of neoadjuvant therapy are to increase A review of the role and position of chemotherapy in the curative resection rate by downstaging the primary multimodality therapy would be timely. The findings of tumor and to improve postoperative survival by eliminating several randomized clinical studies comparing neoadjuvant systemic micrometastases. Chemoradiotherapy (CRT), the CRT and NAC are currently under way and will provide mainstay of preoperative therapy for advanced esophageal some guidance in this regard. cancer in Western countries, has dramatically improved Chemotherapy is the only treatment method that can be local control by increasing the R0 resection rate. However, used to control the systemic spread of esophageal cancer. distant metastasis is common, and two recent randomized However, systemic micrometastases cannot always be clinical studies comparing neoadjuvant CRT and neoadju- eliminated by two or three courses of NAC, and vant chemotherapy (NAC) http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Surgical Oncology Springer Journals

Future Treatment Strategy for Esophageal Cancer Based on Prediction of Systemic Recurrence: Significance of Pathologic Nodal Status After Neoadjuvant Chemotherapy

Yasuda, Takushi
Annals of Surgical Oncology , Volume 25 (8) – May 29, 2018
Download PDF
2 pages

Loading next page...
 
/lp/springer_journal/future-treatment-strategy-for-esophageal-cancer-based-on-prediction-of-DyTjPeYwbZ

References (9)

Publisher
Springer Journals
Copyright
Copyright © 2018 by Society of Surgical Oncology
Subject
Medicine & Public Health; Surgical Oncology; Oncology; Surgery
ISSN
1068-9265
eISSN
1534-4681
DOI
10.1245/s10434-018-6544-0
Publisher site
See Article on Publisher Site

Abstract

Ann Surg Oncol (2018) 25:2127–2128 https://doi.org/10.1245/s10434-018-6544-0 ED ITORIA L – G A STROI N TESTIN A L O NCOL OG Y Future Treatment Strategy for Esophageal Cancer Based on Prediction of Systemic Recurrence: Significance of Pathologic Nodal Status After Neoadjuvant Chemotherapy Takushi Yasuda, MD Department of Surgery, Faculty of Medicine, Kindai University, Osaka-Sayama, Osaka , Japan The main goals of neoadjuvant therapy are to increase A review of the role and position of chemotherapy in the curative resection rate by downstaging the primary multimodality therapy would be timely. The findings of tumor and to improve postoperative survival by eliminating several randomized clinical studies comparing neoadjuvant systemic micrometastases. Chemoradiotherapy (CRT), the CRT and NAC are currently under way and will provide mainstay of preoperative therapy for advanced esophageal some guidance in this regard. cancer in Western countries, has dramatically improved Chemotherapy is the only treatment method that can be local control by increasing the R0 resection rate. However, used to control the systemic spread of esophageal cancer. distant metastasis is common, and two recent randomized However, systemic micrometastases cannot always be clinical studies comparing neoadjuvant CRT and neoadju- eliminated by two or three courses of NAC, and vant chemotherapy (NAC)

Journal

Annals of Surgical Oncology – Springer Journals

Published: May 29, 2018

There are no references for this article.